Hormone replacement therapy as a risk factor for epithelial ovarian cancer: Results of a case-control study

Obstetrics and Gynecology

Volumn 89, Issue 6, 1997, Pages 1012-1016

  Hempling, Ronald E ^a   Wong, Cheung ^a   Piver, M Steven ^a   Natarajan, Nachimuthu ^a   Mettlin, Curtis J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CARCINOGENESIS; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOCARCINOMA; ENDOMETRIOID CARCINOMA; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE; OVARY CARCINOMA; PRIORITY JOURNAL; RISK FACTOR;

CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; LOGISTIC MODELS; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; RISK FACTORS;

EID: 0030904164     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0029-7844(97)00118-X     Document Type: Article

References (29)

1. Bhatia NN, Bergman A, Karram MM. Effects of estrogen on uretheral function in women with urinary incontinence. Am J Obstet Gynecol 1989;160:176-81.
2. Cobpl J, Thonsen JM, Pollen L. Effects of "natural estrogen" replacement therapy on menopausal symptoms and blood clotting. BMJ 1975;4:139-43.
3. Steinfold KA. Treatment of hot flashes with estradiol administration. J Clin Endocrinol Metab 1985;61:627-32.
4. Lindsay R, Hart DM, Clark MD. The minimal effective dose of estrogen for the prevention of post menopausal bone loss. Obstet Gynecol 1984;63:759-63.
5. Felson DT, Zhang S, Hannan MT, Kiel DP, Wilson PW, Anderson JJ. The effect of postmenopausal estrogen therapy or bone density in elderly women. N Engl J Med 1993;329:1141-6.
6. Wild RA. Estrogen effects on the cardiovascular tree. Obstet Gynecol 1996;87:275-355.
7. Sullivan JM, Fowlkes LP. The clinical aspects of estrogen and the cardiovascular system. Obstet Gynecol 1996;87:365-435.
8. Grodstern F, Stampfer MJ, Manson JE, Colditz GA, Willett NG, Rosner B, et al. Post menopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61.
9. Ravnikarvn A. Compliance with hormone therapy. Am J Obstet Gynecol 1987;156:1332-4.
10. Andrews MC. Primary care for postreproductive women: Further thoughts concerning steroid replacement. Am J Obstet Gynecol 1994;170:963-6.
11. Ryan PJ, Hanison R, Blake GM, Fogelman C. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol 1992;99:325-8.
12. Colditz GA, Stampfer MJ, Willet NC, Hunter DJ, Munson JE, Hennekens CH, et al. Type of post menopausal use and risk of breast cancer: 12 year follow-up from the nurses: health study. Cancer Causes Control 1992;3:433-9.
13. Colditz GA, Hankinson SE, Hunter JT, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in post menopausal women. N Engl J Med 1995;332:1589-93.
14. Colditz GA, Egan KM, Stamford NJ. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993;226:1473-80.
15. Ziel HK, Funkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogen. N Engl J Med 1975;293:1167-70.
16. Gambrell RD. Prevention of endometrial cancer with progestins. Maturitas 1986;8:159-68.
17. Projections of the population of the United States: 1977-2050. Current Population Reporting Service no. 704. 1994 United States Bureau of Census, Washington, DC:25.
18. Weiss NS, Lyon JL, Krishnamurthy S, Dietert S, Liff JM, Dailing JR. Noncontraceptive estrogen use and the occurrence of ovarian cancer. J Natl Cancer Inst 1982;68:95-9.
19. Cramer DW, Hutchinson GB, Welch WR, Seully RE, Ryan KJ. Determinants of ovarian cancer risk. I. Reproductive experience and family history. J Natl Cancer Inst 1983;71:711-6.
20. Risch HA. Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol 1996;63:254-7.
21. Polychronopoulou A, Tzonov A, Hsich C, Kaprinis G, Rebelakoc A, Toupadaki N, et al. Reproductive variables, tobacco, ethanol, coffee, and somatometry as risk factors for ovarian cancer. Int J Cancer 1993;55:402-7.
22. Rodriguez C, Calle EE, Coates RJ, Miracle-McMahill HL, Thun MJ, Heath CW Jr. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995;141:828-35.
23. Kaufman DW, Kelly JP, Welch WR, Rosenburg L, Stolley PD, Warshauer ME, et al. Noncontraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989;130:1142-51.
24. Hildreth NG, Kelsey J, Livolsi VA, Fischer DB, Holford TR, Mostow ED, et al. An epidemiologic study of epithelial carcinoma of the ovary. Am J Epidemiol 1981;114:398-405.
25. Whittemore AS, Wu ML, Paffenbarger RS Jr, Sarles DL, Kambert JB, Grosser S, et al. Personal and environmental characteristics related to epithelial ovarian cancer: II. Exposures to talcum powder, tobacco, alcohol, and coffee. Am J Epidemiol 1988;128:1228-40.
26. Hartge P, Hoover R, McGowan L, Lesher L, Norris HJ. Menopause and ovarian cancer. Am J Epidemiol 1988;127:990-8.
27. Whittemore AS, Harris R, Itnyre J, and the Collaboration Ovarian Cancer Group. Characteristics relating to ovarian cancer risks: Collaborative analysis of 12 US case-control studies. Am J Epidemiol 1992;136:1184-203.
28. Shu OS, Gao YT, Yua JM, Ziegler RG, Brinton LA. Dietary factors in epithelial ovarian cancer. Br J Cancer 1989;1:92-6.
29. Harlow BL, Cramer DW, Bell DA, Welch WR. Perineal exposure to talc and ovarian cancer risk. Obstet Gynecol 1992;80:19-26.